Compare MIST & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIST | STXS |
|---|---|---|
| Founded | 2003 | 1990 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.3M | 177.0M |
| IPO Year | 2019 | 2004 |
| Metric | MIST | STXS |
|---|---|---|
| Price | $1.52 | $1.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $8.50 | $4.00 |
| AVG Volume (30 Days) | ★ 2.2M | 373.6K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $29,346,617.00 |
| Revenue This Year | $2,915.14 | $34.08 |
| Revenue Next Year | N/A | $35.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.63 | $1.56 |
| 52 Week High | $3.06 | $3.59 |
| Indicator | MIST | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 52.12 | 46.17 |
| Support Level | $1.38 | $1.74 |
| Resistance Level | $2.01 | $1.95 |
| Average True Range (ATR) | 0.14 | 0.09 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 65.19 | 52.63 |
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.